全球癌症生物标记市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

癌症生物标记市场的成长驱动因素

全球癌症生物标记市场是肿瘤诊断和治疗领域中一个快速发展的细分市场，在癌症早期检测、治疗方案选择和疾病监测方面发挥关键作用。 癌症生物标记是由肿瘤产生或身体内部响应癌症而产生的生物分子，可透过基因组学和蛋白​​质组学技术实现非侵入性且精准的诊断。

市场规模及预测

根据 Fortune Business Insights 预测，2025 年全球癌症生物标记市场规模预计为 428.7 亿美元。预计到 2026 年将成长至 482 亿美元，到 2034 年将达到 836.1 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 7.13%。

这一持续成长反映了癌症发病率的上升、诊断技术的进步以及生物标誌物在个人化医疗和药物研发中应用范围的不断扩大。

市场概览

癌症生物标记广泛应用于癌症诊断、预后预测、药物发现与开发、伴随诊断和个人化医疗等领域。这些生物标记透过促进早期检测、评估疾病进展和支持治疗决策，显着改善患者的治疗效果。

精准肿瘤学需求的不断增长以及生物标记在临床工作流程中的整合，正提升其在全球医疗保健系统中的重要性。此外，学术机构与市场参与者之间的研究合作正在加速生物标记的发现和验证。

主要市场驱动因子

全球癌症发生率的不断上升是癌症生物标记市场的主要驱动因素之一，这推动了对早期诊断和标靶治疗的需求。生物标记越来越多地应用于疾病风险评估、治疗反应评估和伴随诊断，进一步促进了市场扩张。

此外，强大的研发投入也在推动创新。 根据美国国家医学图书馆统计，目前约有 1515 种癌症生物标记正在进行临床试验，这凸显了强大的研发管线，预计将在预测期内推动市场成长。

市场限制因子

儘管成长前景强劲，但市场仍面临诸多挑战，包括新兴国家和已开发国家对生物标记检测的报销政策不足。癌症诊断和治疗费用高昂，尤其是在发展中国家，这限制了患者获得生物标记检测的机会，并促使他们依赖成本更低的替代方案，从而在一定程度上抑制了市场成长。

市场区隔分析

依癌症类型划分

依癌症类型划分，市场可细分为乳癌、肺癌、大肠癌、摄护腺癌和其他癌症。

乳癌细分市场占主导地位，预计到 2026 年将保持 32.59% 的市场占有率，这主要得益于乳癌的高发病率、公众意识的提高以及对新型生物标誌物的持续研究。

肺癌细分市场预计在预测期内将以显着的复合年增长率成长，这主要归功于研发投入的增加和全球肺癌发生率的上升。

依生物标记类型划分

依生物标记类型划分，市场包括 PSA、HER-2、EGFR、KRAS 等。

由于HER-2在乳癌诊断的广泛应用，预计到2026年，其市占率将达到33.34%，成为最大的市占率。预计到2025年，HER-2市占率将达到142.5亿美元。

同时，由于肺癌发生率的上升，预计EGFR生物标记市场占有率将以更快的速度增长。

依最终使用者划分

依最终用户划分，市场可分为诊断和研究机构、製药和生物技术公司、医院和专科诊所以及其他机构。

到2026年，诊断和研究机构将占市场主导地位，市场占有率将达到53.49%，这主要得益于检测量的增加和先进诊断试剂盒的推出。由于生物标记在药物发现和开发中的应用日益广泛，製药和生物技术公司也看到了需求的成长。

区域分析

北美将引领全球癌症生物标记市场，2025年市占率将达35.94%，2026年市场规模将达172.9亿美元。预计到2026年，美国市场规模将达到150.3亿美元，这得益于先进的诊断技术和强大的研发基础设施。

欧洲市场规模位居第二，预计到2026年，英国市场规模将达21.9亿美元，德国市场规模将达38亿美元。

由于医疗保健投资的增加和基于生物标誌物的诊断技术的应用，亚太地区预计将以显着的复合年增长率增长。 预计到 2026 年，印度市场规模将达到 13.5 亿美元，日本市场规模预计将达到 34 亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

• 市场驱动因素
• 市场限制因素
• 市场机遇

第四章：关键考虑因素

• 主要地区和国家的盛行率/发生率：依癌症类型划分
• 主要公司新产品发布状况
• 产品线分析：癌症生物标记市场
• 主要产业趋势：併购（併购），商业合作

第五章：全球癌症生物标记市场分析：洞察与预测（2021-2034）

• 主要分析结果/摘要
• 市场分析、洞察与预测：依癌症类型划分
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 摄护腺癌
  • 其他
• 市场分析、洞察与预测：依生物标记类型划分
  • PSA
  • HER-2
  • EGFR
  • KRAS
  • 其他
• 市场分析、洞察与预测：依最终用户划分
  • 製药和生技公司
  • 诊断与研究机构
  • 医院和专科医院诊所
  • 其他
• 市场分析、洞察与预测：依地区划分
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第六章 北美癌症生物标记市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 美国
  • 加拿大

第七章 欧洲癌症生物标记市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 美国王国
  • 德国
  • 法国
  • 西班牙
  • 义大利
  • 斯堪的纳维亚
  • 欧洲其他地区

第八章 亚太地区癌症生物标记市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 东南亚
  • 亚太其他地区

第九章 拉丁美洲癌症生物标记市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区美国

第十章：中东与非洲癌症生物标记市场分析：洞察与预测（2021-2034）

• 依国家划分
  • 海湾合作委员会 (GCC) 国家
  • 南非
  • 中东和非洲其他地区

第十一章：竞争分析

• 主要行业趋势
• 全球市占率分析（2025）
• 公司简介
• F. Hoffmann-La Roche Ltd.
• Abbott
• CENTOGENE N.V.
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Axon Medchem
• Sino Biological Inc.
• R&D;System
• BioVision Inc.
• Myriad RBM
• Other Prominent Players

第 12 章：策略建议

Growth Factors of cancer biomarkers Market

The global cancer biomarkers market is a rapidly evolving segment of the oncology diagnostics and therapeutics landscape, playing a critical role in early cancer detection, treatment selection, and disease monitoring. Cancer biomarkers are biological molecules produced by tumors or generated by the body in response to cancer, enabling non-invasive and precise diagnosis through genomics and proteomics technologies.

Market Size and Forecast

According to Fortune Business Insights, the global cancer biomarkers market was valued at USD 42.87 billion in 2025. The market is projected to grow to USD 48.2 billion in 2026 and further reach USD 83.61 billion by 2034, registering a CAGR of 7.13% during the forecast period (2026-2034).

This sustained growth reflects increasing cancer prevalence, technological advancements in diagnostics, and expanding applications of biomarkers in personalized medicine and drug development.

Market Overview

Cancer biomarkers are extensively used across applications such as cancer diagnostics, prognostics, drug discovery and development, companion diagnostics, and personalized medicine. These biomarkers facilitate early disease detection, assess disease progression, and support treatment decision-making, significantly improving patient outcomes.

The increasing demand for precision oncology, along with the integration of biomarkers into clinical workflows, is strengthening their importance across healthcare systems globally. Furthermore, research collaborations between academic institutions and market players are accelerating biomarker discovery and validation.

Key Market Drivers

One of the primary drivers of the cancer biomarkers market is the rising global incidence of cancer, leading to growing demand for early diagnosis and targeted therapies. Biomarkers are increasingly used in disease risk assessment, therapy response evaluation, and companion diagnostics, fueling market expansion.

Additionally, strong research and development investments are driving innovation. According to the U.S. National Library of Medicine, approximately 1,515 cancer biomarkers are currently under clinical trials, highlighting a robust development pipeline that is expected to strengthen market growth during the forecast period.

Market Restraints

Despite strong growth prospects, the market faces challenges such as lack of reimbursement policies for biomarker testing in both emerging and developed economies. The high cost of cancer diagnosis and treatment, particularly in developing countries, limits patient access to biomarker testing and encourages reliance on lower-cost alternatives, restraining market growth to some extent.

Market Segmentation Analysis

By Cancer Type

Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.

The breast cancer segment dominated the market and is expected to hold a 32.59% share in 2026, driven by high disease prevalence, increased awareness, and ongoing research into novel biomarkers.

The lung cancer segment is anticipated to grow at a significant CAGR during the forecast period due to rising R&D investments and increasing lung cancer incidence globally.

By Biomarker Type

By biomarker type, the market includes PSA, HER-2, EGFR, KRAS, and others.

The HER-2 segment held the largest share, accounting for 33.34% in 2026, supported by its widespread use in breast cancer diagnosis. The HER-2 segment is projected to generate USD 14.25 billion in revenue by 2025.

Meanwhile, the EGFR biomarker segment is expected to grow at a faster pace, driven by increasing lung cancer prevalence.

By End User

Based on end user, the market is segmented into diagnostics & research laboratories, pharmaceutical & biotechnology companies, hospitals & specialty clinics, and others.

The diagnostics & research laboratories segment dominated the market with a 53.49% share in 2026, supported by rising test volumes and introduction of advanced diagnostic kits. Pharmaceutical and biotechnology companies are also witnessing growing demand due to increased use of biomarkers in drug discovery and development.

Regional Analysis

North America dominated the global cancer biomarkers market with a 35.94% share in 2025 and was valued at USD 17.29 billion in 2026. The U.S. market is projected to reach USD 15.03 billion by 2026, supported by advanced diagnostic technologies and strong R&D infrastructure.

Europe follows North America, with the UK projected to reach USD 2.19 billion and Germany USD 3.8 billion by 2026.

The Asia Pacific region is expected to grow at a significant CAGR, driven by increasing healthcare investments and adoption of biomarker-based diagnostics. The India market is projected to reach USD 1.35 billion by 2026, while Japan is expected to reach USD 3.40 billion by 2026.

Competitive Landscape

The cancer biomarkers market is semi-consolidated, with leading players including F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific, Bio-Rad Laboratories, and CENTOGENE N.V. Companies are focusing on new product launches, strategic collaborations, and regulatory approvals to strengthen their market position.

Conclusion

In conclusion, the global cancer biomarkers market is poised for strong growth from USD 42.87 billion in 2025 to USD 83.61 billion by 2034, driven by rising cancer prevalence, expanding applications in personalized medicine, and a strong pipeline of biomarker innovations. Despite reimbursement and cost-related challenges, continued advancements in diagnostics and increased research collaborations are expected to sustain long-term market expansion across developed and emerging regions.

Segmentation By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

By Biomarker Type

• PSA
• HER-2
• EGFR
• KRAS
• Others

By End User

• Pharmaceutical & Biotechnology Companies
• Diagnostics & Research Laboratories
• Hospitals & Specialty Clinics
• Others

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
• 4.2. New Product Launches, by Key Market Players
• 4.3. Pipeline Analysis, Cancer Biomarkers
• 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships

5. Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.2.1. Lung Cancer
  • 5.2.2. Breast Cancer
  • 5.2.3. Colorectal Cancer
  • 5.2.4. Prostate Cancer
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 5.3.1. PSA
  • 5.3.2. HER-2
  • 5.3.3. EGFR
  • 5.3.4. KRAS
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. Diagnostics & Research Laboratories
  • 5.4.3. Hospitals & Specialty Clinics
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 6.2.1. Lung Cancer
  • 6.2.2. Breast Cancer
  • 6.2.3. Colorectal Cancer
  • 6.2.4. Prostate Cancer
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 6.3.1. PSA
  • 6.3.2. HER-2
  • 6.3.3. EGFR
  • 6.3.4. KRAS
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. Diagnostics & Research Laboratories
  • 6.4.3. Hospitals & Specialty Clinics
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 7.2.1. Lung Cancer
  • 7.2.2. Breast Cancer
  • 7.2.3. Colorectal Cancer
  • 7.2.4. Prostate Cancer
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 7.3.1. PSA
  • 7.3.2. HER-2
  • 7.3.3. EGFR
  • 7.3.4. KRAS
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. Diagnostics & Research Laboratories
  • 7.4.3. Hospitals & Specialty Clinics
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 8.2.1. Lung Cancer
  • 8.2.2. Breast Cancer
  • 8.2.3. Colorectal Cancer
  • 8.2.4. Prostate Cancer
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 8.3.1. PSA
  • 8.3.2. HER-2
  • 8.3.3. EGFR
  • 8.3.4. KRAS
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. Diagnostics & Research Laboratories
  • 8.4.3. Hospitals & Specialty Clinics
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 9.2.1. Lung Cancer
  • 9.2.2. Breast Cancer
  • 9.2.3. Colorectal Cancer
  • 9.2.4. Prostate Cancer
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 9.3.1. PSA
  • 9.3.2. HER-2
  • 9.3.3. EGFR
  • 9.3.4. KRAS
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. Diagnostics & Research Laboratories
  • 9.4.3. Hospitals & Specialty Clinics
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Biomarkers Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 10.2.1. Lung Cancer
  • 10.2.2. Breast Cancer
  • 10.2.3. Colorectal Cancer
  • 10.2.4. Prostate Cancer
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Biomarker Type
  • 10.3.1. PSA
  • 10.3.2. HER-2
  • 10.3.3. EGFR
  • 10.3.4. KRAS
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. Diagnostics & Research Laboratories
  • 10.4.3. Hospitals & Specialty Clinics
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.3.1. F. Hoffmann-La Roche Ltd.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Products & services,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Abbott
    • 11.3.2.1. Overview,
    • 11.3.2.2. Products & services,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. CENTOGENE N.V.
    • 11.3.3.1. Overview,
    • 11.3.3.2. Products & services,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Bio-Rad Laboratories, Inc.
    • 11.3.4.1. Overview,
    • 11.3.4.2. Products & services,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. CENTOGENE N.V.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Products & services,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Axon Medchem
    • 11.3.6.1. Overview,
    • 11.3.6.2. Products & services,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Sino Biological Inc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Products & services,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. R&D System
    • 11.3.8.1. Overview,
    • 11.3.8.2. Products & services,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. BioVision Inc.
    • 11.3.9.1. Overview,
    • 11.3.9.2. Products & services,
    • 11.3.9.3. SWOT analysis,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)
  • 11.3.10. Myriad RBM
    • 11.3.10.1. Overview,
    • 11.3.10.2. Products & services,
    • 11.3.10.3. SWOT analysis,
    • 11.3.10.4. Recent developments,
    • 11.3.10.5. strategies,
    • 11.3.10.6. financials (based on availability)
  • 11.3.11. Other Prominent Players
    • 11.3.11.1. Overview,
    • 11.3.11.2. Products & services,
    • 11.3.11.3. SWOT analysis,
    • 11.3.11.4. Recent developments,
    • 11.3.11.5. strategies,
    • 11.3.11.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

• Table 1: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 2: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 3: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 4: Global Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
• Table 5: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 6: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 7: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 8: North America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
• Table 9: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 10: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 11: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 12: Europe Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
• Table 13: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 14: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 15: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 16: Asia Pacific Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
• Table 17: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 18: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 19: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 20: Latin America Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
• Table 21: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Cancer Type, 2021-2034
• Table 22: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by Biomarker Type, 2021-2034
• Table 23: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
• Table 24: Middle East & Africa Cancer Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

• Figure 1: Global Cancer Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
• Figure 2: Global Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025 & 2034
• Figure 3: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer, 2021-2034
• Figure 4: Global Cancer Biomarkers Market Forecast (US$ Mn), by Breast Cancer, 2021-2034
• Figure 5: Global Cancer Biomarkers Market Forecast (US$ Mn), by Colorectal Cancer, 2021-2034
• Figure 6: Global Cancer Biomarkers Market Forecast (US$ Mn), by Prostate Cancer, 2021-2034
• Figure 7: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
• Figure 8: Global Cancer Biomarkers Market Value Share (%), by Biomarker Type 2025 & 2034
• Figure 9: Global Cancer Biomarkers Market Forecast (US$ Mn), by PSA, 2021-2034
• Figure 10: Global Cancer Biomarkers Market Forecast (US$ Mn), by HER-2, 2021-2034
• Figure 11: Global Cancer Biomarkers Market Forecast (US$ Mn), by EGFR, 2021-2034
• Figure 12: Global Cancer Biomarkers Market Forecast (US$ Mn), by KRAS 2021-2034
• Figure 13: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
• Figure 14: Global Cancer Biomarkers Market Value Share (%), by End User, 2025 & 2034
• Figure 15: Global Cancer Biomarkers Market Forecast (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2021-2034
• Figure 16: Global Cancer Biomarkers Market Forecast (US$ Mn), by Lung Cancer & Research Laboratories, 2021-2034
• Figure 17: Global Cancer Biomarkers Market Forecast (US$ Mn), by Hospitals & Speciality Clinics, 2021-2034
• Figure 18: Global Cancer Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
• Figure 19: Global Cancer Biomarkers Market Value (US$ Mn), by Region, 2025 & 2034
• Figure 20: North America Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
• Figure 21: North America Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
• Figure 22: North America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
• Figure 23: North America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
• Figure 24: North America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
• Figure 25: North America Cancer Biomarkers Market Value Share (%), by End User, 2025
• Figure 26: North America Cancer Biomarkers Market Value (US$ Mn), By Country, 2025 & 2034
• Figure 27: North America Cancer Biomarkers Market Value Share (%), By Country, 2025
• Figure 28: Europe Cancer Biomarkers Market Value (US$ Mn), by Cancer Cancer Type, 2025 & 2034
• Figure 29: Europe Cancer Biomarkers Market Value Share (%), by Cancer Cancer Type, 2025
• Figure 30: Europe Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
• Figure 31: Europe Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
• Figure 32: Europe Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
• Figure 33: Europe Cancer Biomarkers Market Value Share (%), by End User, 2025
• Figure 34: Europe Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
• Figure 35: Europe Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
• Figure 36: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
• Figure 37: Asia Pacific Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
• Figure 38: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
• Figure 39: Asia Pacific Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
• Figure 40: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
• Figure 41: Asia Pacific Cancer Biomarkers Market Value Share (%), by End User, 2025
• Figure 42: Asia Pacific Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
• Figure 43: Asia Pacific Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
• Figure 44: Latin America Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
• Figure 45: Latin America Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
• Figure 46: Latin America Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
• Figure 47: Latin America Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
• Figure 48: Latin America Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
• Figure 49: Latin America Cancer Biomarkers Market Value Share (%), by End User, 2025
• Figure 50: Latin America Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
• Figure 51: Latin America Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
• Figure 52: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Cancer Type, 2025 & 2034
• Figure 53: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Cancer Type, 2025
• Figure 54: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by Biomarker Type, 2025 & 2034
• Figure 55: Middle East & Africa Cancer Biomarkers Market Value Share (%), by Biomarker Type, 2025
• Figure 56: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
• Figure 57: Middle East & Africa Cancer Biomarkers Market Value Share (%), by End User, 2025
• Figure 58: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
• Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
• Figure 60: Global Cancer Biomarkers Market Share (%), By Company, 2025